Early-life adversity and neurological disease: age-old questions and novel answers
Related Experiment Video
Updated: Jan 19, 2026

Author Spotlight: Exploring Microglial Interactions with Stress-Response Circuitry Using the Limited Bedding and Nesting Model
Published on: July 12, 2024
Annabel K Short1,2, Tallie Z Baram3,4,5
1Departments of Anatomy and Neruobiology, University of California-Irvine, Irvine, CA, USA.
Abstract:
Neurological illnesses, including cognitive impairment, memory decline and dementia, affect over 50 million people worldwide, imposing a substantial burden on individuals and society. These disorders arise from a combination of genetic, environmental and experiential factors, with the latter two factors having the greatest impact during sensitive periods in development. In this Review, we focus on the contribution of adverse early-life experiences to aberrant brain maturation, which might underlie vulnerability to cognitive brain disorders. Specifically, we draw on recent robust discoveries from diverse disciplines, encompassing human studies and experimental models. These discoveries suggest that early-life adversity, especially in the perinatal period, influences the maturation of brain circuits involved in cognition. Importantly, new findings suggest that fragmented and unpredictable environmental and parental signals comprise a novel potent type of adversity, which contributes to subsequent vulnerabilities to cognitive illnesses via mechanisms involving disordered maturation of brain 'wiring'.
Related Concept Videos
04:20Limited Bedding and Nesting as a Model for Early-Life Adversity in Mice
07:04Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans
09:58Lipidomics and Transcriptomics in Neurological Diseases
06:19Reconstruction of the Blood-Brain Barrier In Vitro to Model and Therapeutically Target Neurological Disease
12:24Quantifying Yeast Chronological Life Span by Outgrowth of Aged Cells
06:49A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

